



an Open Access Journal by MDPI

The Story of Successful Drugs and Recent FDA-Approved Molecules

Guest Editors:

Dr. Jean Jacques Vanden Eynde

Prof. Dr. Klaus Kopka

Dr. Maria Emília De Sousa

Dr. Annie Mayence

Prof. Dr. Joachim Jose

Prof. Dr. Guangshun Wang

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

In 2018, the FDA approved 59 novel drugs, a record high, demonstrating the vigor of pharmaceutical industry and associated research groups. Small molecules were the most represented entities among the approvals, but there is an increasing number of antibodies and oligonucleotides on the medical market. Interestingly, there is a growing interest in the development of orphan drugs and the treatment of orphan diseases.

The aim of this Special Issue is to offer to our readers short but comprehensive and updated reviews on compounds recently approved by the FDA and drugs attracting particular attention because of their success.

Dr. Jean Jacques Vanden Eynde

Prof. Dr. Klaus Kopka

Prof. Dr. Maria Emília De Sousa

Dr. Annie Mayence

Prof. Dr. Joachim Jose

Dr. Guangshun Wang

Guest Editors



mdpi.com/si/25275

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com